Kinase cascades and ligand-directed signaling at the kappa opioid receptor

Psychopharmacology

Volumn 209, Issue 2, 2010, Pages 137-147

  Bruchas, Michael R ^a   Chavkin, Charles ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Arrestin; Depression; Dynorphin; ERK 1 2; GPCR; JNK; Kappa opioid receptor; Kinase; Ligand directed signaling; MAPK; Opioid; P38; Relapse; Stress; Therapeutics

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENYLATE CYCLASE; BETA ARRESTIN; BREMAZOCINE; BUPRENORPHINE; CALCIUM CHANNEL; CYCLIC AMP; DYNORPHIN A; DYNORPHIN B; ETORPHINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALOXONE; PERTUSSIS TOXIN; POTASSIUM CHANNEL; PROTEIN KINASE; SALVINORIN A; STRESS ACTIVATED PROTEIN KINASE; UNINDEXED DRUG; PHOSPHOTRANSFERASE;

ALLODYNIA; ANXIETY; CALCIUM CONDUCTANCE; COMPLEX FORMATION; DEPRESSION; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HYPERALGESIA; INFLAMMATION; INTERNALIZATION; MOOD DISORDER; NONHUMAN; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; ADDICTION; CELL PROLIFERATION; DESENSITIZATION; ENZYME INHIBITION; ION CONDUCTANCE; LIGAND BINDING; MOLECULAR DYNAMICS; PROTEIN TRANSPORT;

ADENYLATE CYCLASE; ANIMALS; CYCLIC AMP; DYNORPHINS; ENZYME ACTIVATION; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, OPIOID, KAPPA; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 77951855896     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1768-0     Document Type: Review

References (109)

1. Appleyard SM, Patterson TA, Jin W, Chavkin C (1997) Agonist-induced phosphorylation of the kappa-opioid receptor. J Neurochem 69:2012-2405
2. Appleyard SM, Celver J, Pineda V, Kovoor A, Wayman GA, Chavkin C (1999) Agonist-dependent desensitization of the kappa opioid receptor by G protein receptor kinase and beta-arrestin. J Biol Chem 274:23802-23807
3. Ariens EJ (1954) Affinity and intrinsic activity in the theory of competitive inhibition I Problems and theory. Arch Int Pharmacodyn Ther 99:32-49
4. Ashwell JD (2006) The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 6:532-540
5. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z (1997) Opiate-induced adenylyl cyclase superactivation is isozymespecific. J Biol Chem 272:5040-5047
6. Baker SJ, Reddy EP (1998) Modulation of life and death by the TNF receptor superfamily. Oncogene 17:3261-3270
7. Barchfeld CC, Medzihradsky F (1984) Receptor-mediated stimulation of brain GTPase by opiates in normal and dependent rats. Biochem Biophys Res Commun 121:641-648
8. Beardsley PM, Howard JT, Shelton KL, Carroll FI (2005) Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 183:118-126
9. Belcheva MM, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, Levy R, Young EC, Barg J, Coscia CJ (1998) Opioid modulation of extracellular signal-regulated protein kinase activity is rasdependent and involves Gbetagamma subunits. Biochemistry 48:6898-6908
10. Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A, Coscia CJ (2005) Mu and kappa opioid receptors activate ERK/ MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem. 280:27662-27669
11. Bhargava HN, Gulati A, Ramarao P (1989) Effect of chronic administration of U-50, 488H on tolerance to its pharmacologicalactions and on multiple opioid receptors ta rat brata regions and spinal cord. J Pharmacol Exp Ther 251:21-26
12. Blake AD, Bot G, Freeman JC, Reisine T (1997) Differential opioid agonist regulation of the mouse mu opioid receptor. J Biol Chem 272:782-790
13. Bruchas MR, Macey TA, Lowe JD, Chavkin C (2006) Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281:18081-18089
14. Bruchas MR, Land BB, Aita M, Xu M, Barot SK, Li S, Chavkin C (2007a) Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27:11614-11623
15. Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C (2007b) Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282:29803-29811
16. Bruchas MR, Xu M, Chavkin C (2008) Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport 19:1417-1422
17. Bruchas MR, Land BB, Lemos J, Chavkin C (2009a) CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One 4(12):e8528
18. Bruchas MR, Land BB, Chavkin C (2009b) The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314C:44-55
19. Carlezon WA, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, Duman RS, Neve RL, Nestler EJ (1998) Regulation of cocaine reward by CREB. Science 282:2272-2275
20. Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28:436-445
21. Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS (2004) Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. Eur J Pharmacol 501:111-119
22. Chan AS, Yeung WW, Wong YH (2005) Integration of G protein signals by extracellular signal-regulated protein kinases in SKN-MC neuroepithelioma cells. Cell. Mol Life Sci 55:1230-1254
23. Chavkin C, James IF, Goldstein A (1982) Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215:413-415
24. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004) Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308:1197-1203
25. Chen Y, Chen C, Liu-Chen LY (2007) Dynorphin peptides differentially regulate the human kappa opioid receptor. Life Sci 80:1439-1448
26. Cheng ZJ, Yu QM, Wu YL, Ma L, Pei G (1998) Selective interference of beta-arrestta 1 with kappa and delta but not mu opioid receptor/G protein coupling. J Biol Chem 273:24328-24333
27. Childers SR, Snyder SH (1978) Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. Life Sci 23:759-761
28. Clark AJ (1926) The reaction between acetyl choline and muscle cells. J Physiol 61:530-546
29. Clayton CC, Xu M, Chavkin C (2009) Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization. J Biol Chem 284:31872-31881
30. Crain SM, Shen KF (1990) Opioids can evoke direct receptormediated excitatory as well as inhibitory effects on sensory neuron action potentials. NIDA Res Monogr 105:34-39
31. Della Rocca GJ, Maudsley S, Daaka Y, Lefkowitz RJ, Luttrell LM (1999) Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade Role of focal adhesions and receptor tyrosine kinases. J Biol Chem 274:13978-13984
32. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (1996) International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48:567-592
33. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, Lefkowitz RJ (2006) Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864
34. Grudt TJ, Williams JT (1995) Opioid receptors and the regulation of ion conductances. Rev Neurosci 6:279-286
35. Gurwell JA, Duncan MJ, Maderspach K, Stiene-Martin A, Eide RP, Hauser KF (1996) Kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids. Brata Res 737:175-187
36. Horan P, Taylor J, Yamamura HI, Porreca F (1992) Extremely longlasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237-1243
37. Hsia JA, Moss J, Hewlett EL, Vaughan M (1984) ADP-ribosylation of adenylate cyclase by pertussis toxin: effects on inhibitory agonist binding. J Biol Chem 25:1086-1090
38. Hudmon A, Choi JS, Tyrrell L, Black JA, Rush AM, Waxman SG, Dib-Hajj SD (2008) Phosphorylation of sodium channel Na(v)18 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 28:3190-3201
39. Hunton DL, Barnes WG, Kim J, Ren XR, Violin JD, Reiter E, Milligan G, Patel DD, Lefkowitz RJ (2005) Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of Chemotaxis. Mol Pharmacol 67:1229-1236
40. Jordan BA, Cvejic S, Devi LA (2000) Kappa opioid receptor endocytosis by dynorphin peptides. DNA Cell Biol 19:19-27
41. Kam AY, Chan AS, Wong YH (2004) Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptorinduced activation of c-Jun N-terminal kinase. J Neurochem 89:391-402
42. Karandikar M, Cobb MH (1999) Scaffolding and protein interactions in MAP kinase modules. Cell Calcium 26:219-226
43. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354
44. Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415
45. Kim E, Clark. AL, Kiss A, Hahn JW, Wesselschmidt R, Coscia CJ, Belcheva MM (2006) Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem 281:33749-33760
46. Knoll AT, Carlezon WA (2010) Dynorphin, stress, and depression. Brain Res 1314:56-73
47. Kohout TA, Lefkowitz RJ (2003) Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 63:9-18
48. Kreek MJ, Koob GF (1998) Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51:23-47
49. Kreek MJ, Zhou Y, Butelman ER, Levran O (2009) Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opta Pharmacol 9(1):74-80
50. Kreibich AS, Blendy JA (2004) cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci 24:6686-6692
51. Kukkonen JP, Näsman J, Rinken A, Dementjev A, Akerman KE (1998) Pseudo-noncompetitive antagonism of Ml, M3, and M5muscarinic receptor-mediated Ca2+ mobilization by muscarinic antagonists. Biochem Biophys Res Commun 243:41-46
52. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28:407-414
53. Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D, Hnasko TS, Palmiter RD, Chavkin C (2009) Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci USA 106:19168-19173
54. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308:512-517
55. Li JG, Luo LY, Krupnick JG, Benovic JL, Liu-Chen LY (1999) U50, 488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamta-dependent mechanism Kappa receptor internalization is not required for mitogenactivated protein kinase activation. J Biol Chem 274:12087-12094
56. Li J, Li JG, Chen C, Zhang F, Liu-Chen LY (2002) Molecular basis of differences in (-)(trans)-3, 4-dichloro-N-methyl-N-[2-(l-pyrrolidiny)- cyclohexyl]benzeneacetamide-induced desensitization and phosphorylation between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 61:73-84
57. Li JG, Zhang F, Jin XL, Liu-Chen LY (2003) Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50, 488H-induced internalization and phosphorylation. J Pharmacol Exp Ther 305:531-540
58. Liu-Chen LY (2004) Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 75:511-536
59. Lopez-Ilasaca M (1998) Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 56:269-277
60. Lozama A, Prisinzano TE (2009) Chemical methods for the synthesis and modification of neoclerodane diterpenes. Bioorg Med. Chem Lett 19:5490-5495
61. Martaissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368-376
62. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ (2000) Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574-1577
63. McLaughlin JP, Marton-Popovici M, Chavkin C (2003a) Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683
64. McLaughlin JP, Xu M, Mackie K, Chavkin C (2003b) Phosphorylation of a carboxyl-terminal serine within the kappa-opioid receptor produces desensitization and internalization. J Biol Chem 278:34631-34640
65. McLaughlin JP, Myers LC, Zarek PE, Caron MG, Lefkowitz RJ, Czyzyk TA, Pintar JE, Chavkin C (2004) Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem 279:1810-1818
66. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C (2006) Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31:1241-1248
67. McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, Mohabbat Y, Moyer RA, Bohn LM, Coscia CJ (2008) Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem 107:1753-1765
68. Minden A, Karin M (1998) Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1333:F85-F104
69. Minneman KP, Iversen IL (1976) Enkephalin and opiate narcotics increase cyclic GMP accumulation in slices of rat neostriatum. Nature 262:313-314
70. Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS (2002) Kappa opioid antagonist effects of the novel kappa antagonist 5′- guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) 163:412-419
71. Nobes C, Hall A (1994) Regulation and function of the Rho subfamily of small GTPases. Curr Opin Genet Dev 4:77-81
72. Pan ZZ (2003) Kappa-opioid receptor-mediated enhancement of the hyperpolarization-activated current (1(h)) through mobilization of intracellular calcium in rat nucleus raphe magnus. J Physiol 548:765-775
73. Perez DM, Karnik SS (2005) Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57:147-161
74. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776
75. Pierce KL, Lefkowitz RJ (2001) Classical and new roles of betaarrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci. 2:727-733
76. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ (2001) Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream, and downstream of heparta-binding EGF shedding. J Biol Chem 276:23155-23160
77. Piñeyro G (2009) Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling. Cell Signal 21:179-185
78. Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy S, Shelton RC, Hewlett WA, Sutcliffe JS, Blakely RD (2005) Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci USA 102:11545-11550
79. Raman M, Chen W, Cobb MH (2007) Differential regulation and properties of MAPKs. Oncogene 26:3100-3112
80. Raynor K, Kong H, Hines J, Kong G, Benovic J, Yasuda K, Bell GI, Reisine T (1994) Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor. J Pharmacol Exp Ther 270:1381-1386
81. Redila VA, Chavkin C (2008) Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl.) 200:59-70
82. Rockman MV, Hahn MW, Soranzo N, Zimprich F, Goldstein DB, Wray G (2005) Ancient and recent positive selection transformed opioid cis-regulation in humans. PLoS Biol 3:e387
83. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939
84. Rumbaugh G, Adams JP, Kim JH (2006) Huganir RL (2006) SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. Proc Natl Acad Sci U S A 103: 4344-4351
85. Rusin KI, Giovannucci DR, Stuenkel EL, Moises HC (1997) Kappa-opioid receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals. J Neurosci 17:6565-6574
86. Sadja R, Alagem N, Reuveny E (2003) Gating of GIRK channels: details of an intricate, membrane-delimited signaling complex. Neuron 39:9-12
87. Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S (2005) A role for p38 mitogen-activated protein kinase in the regulation of theSerotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci. 25:29-41
88. Shahabi NA, McAllen K, Sharp BM (2006) delta opioid receptors stimulate Akt-dependent phosphorylation of c-jun in T cells. J Pharmacol Exp Ther 316:933-939
89. Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (2006) Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70:1264-1270
90. Song X, Coffa S, Fu H, Gurevich VV (2009) How does arrestin assemble MAPKs into a signaling complex? J Biol Chem 284:685-695
91. Spencer RJ, Jin W, Thayer SA, Chakrabarti S, Law PY, Loh HH (1997) Mobilization of Ca2+ from intracellular stores in transfected neuro2a cells by activation of multiple opioid receptor subtypes. Biochem Pharmacol 7:809-818
92. Steiner JA, Carneiro AM, Blakely RD (2008) Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Traffic 9:1393-1402
93. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11:379-393
94. Stiene-Martin A, Mattson MP, Hauser KF (1993) Opiates selectively increase intracellular calcium in developing type-1 astrocytes: role of calcium in morphine-induced morphologic differentiation. Brain Res Dev Brain Res 76:189-196
95. Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14:311-317
96. Taussig R, lñigucz-Lluhi JA, Gilman AG (1993) Inhibition of adenylyl cyclase by Gi alpha. Science 261:218-221
97. Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5:173-183
98. Tibbles LA, Woodgett JR (1999) The stress-activated protein kinase pathways. Trends Neurosci 28:436-445
99. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13
100. Violin JD, Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seven transmembrane receptors. Trends Pharmacol Sci 28:416-422
101. Walker BM, Koob GF (2008) Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33:643-652
102. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY (2005) Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3 FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-230
103. Wang Y, Chen Y, Xu W, Lee DY, Ma Z, Rawls SM, Cowan A, Liu-Chen LY (2008) 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. J Pharmacol Exp Ther 324: 1073-1083
104. Watkins LR, Milligan ED, Maier SF (2001) Glial activation: a driving force for pathological pain Trends Neurosci 24:450-455
105. Wickman KD, Clapham DE (1995) G-protein regulation of ion channels. Curr Opta Neurobiol 5(3):278-285
106. Xu M, Bruchas MR, Ippolito DL, Gendron L, Chavkin C (2007) Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase J Neurosci 27:2570-2581
107. Yan F, Bikbulatov RV, Mocanu V, Dicheva N, Parker CE, Wetsel WC, Mosier PD, Westkaemper RB, Allen JA, Zjawiony JK, Roth BL (2009) Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry 48:6898-6908
108. Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005) p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 280:15649-15658
109. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, Ji RR (2006) A peptide c-Jun N-terrninal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 26:3551-3560